|
| Characteristics | Overall (n = 82) | CD (n = 63) | UC (n = 19) |
|
| Age (years), median (IQR) | 39.0 (27.8–48.0) | 38.0 (27.0–47.0) | 46.0 (34.0–58.0) |
| Female, n (%) | 41 (50.0) | 30 (47.6) | 11 (57.9) |
| Body mass index (kg/m2), mean (SD) | 24.0 (22.0–28.0) | 24.0 (22.0–28.0) | 23.8 (21.3–29.5) |
| Active smoking, n (%) | 5 (6.1) | 5 (7.9) | 0 |
| Duration of IBD (year), median (IQR) | 11.5 (6.0–20.2) | 12.0 (7.0–21.0) | 11.0 (2.0–20.0) |
| Concomitant therapy for IBD, n (%) |
| 5-Aminosalicylates | 18 (22.0) | 7 (11.1) | 11 (57.9) |
| Thiopurines | 3 (3.7) | 3 (4.8) | 0 |
| Sulfasalazine | 3 (3.7) | 2 (3.2) | 1 (5.3) |
| Systemic corticosteroids | 9 (11.0) | 4 (6.3) | 5 (26.3) |
| Steroid dose (mg/d), median (IQR) | 20.0 (7.5–40.0) | 7.5 (5.0–32.5) | 20.0 (17.5–45.0) |
| Methotrexate | 1 (1.2) | 1 (1.6) | 0 |
| Biologics, n (%) | 59 (72.0) | 49 (77.8) | 10 (52.6) |
| Infliximaba | 11 (18.6) | 8 (16.3) | 3 (30.0) |
| Adalimumab | 18 (30.5) | 16 (32.7) | 2 (20.0) |
| Vedolizumaba | 6 (10.2) | 4 (8.2) | 2 (20.0) |
| Ustekinumaba | 21 (35.6) | 20 (40.8) | 1 (10.0) |
| Tofacitiniba | 1 (1.7) | 0 | 1 (10.0) |
| Other biologics (clinical trial study)a | 2 (3.4) | 1 (2.0) | 1 (10.0) |
| Previous expose to biologics | 29 (35.4) | 27 (42.9) | 2 (10.5) |
| Number of comorbidities, n (%) |
| None | 54 (65.9) | 43 (68.3) | 11 (55.6) |
| 1 | 18 (22.0) | 12 (19.0) | 6 (33.3) |
| 2 | 7 (8.5) | 5 (7.9) | 2 (11.1) |
| 3 | 1 (1.2) | 1 (1.6) | 0 |
| ≥4 | 2 (2.4) | 2 (3.2) | 0 |
| Major comorbidity, n (%) |
| Cardiovascular disease | 8 (9.8) | 8 (12.7) | 0 |
| Chronic lung disease | 7 (8.5) | 4 (6.3) | 3 (15.8) |
| Diabetes mellitus | 5 (6.1) | 5 (7.9) | 0 |
| Obesity (BMI >30 kg/m2) | 14 (17.1) | 10 (15.9) | 4 (21.1) |
| Immune-mediated diseases | 6 (7.3) | 4 (6.3) | 2 (10.5) |
| Malignancies | 2 (2.4) | 1 (1.6) | 1 (5.3) |
| Chronic renal disease | 1 (1.2) | 1 (1.6) | 0 |
| IBD characteristics, n (%) |
| UC type |
| E1/E2/E3 | NA | NA | 1 (5.3)/9 (47.4)/9 (47.4) |
| S1/S2/S3 | NA | NA | 5 (26.3)/13 (68.4)/1 (5.3) |
| CD type |
| L1/L2/L3/L4 | NA | 12 (19.0)/18 (28.6)/30 (47.6)/3 (4.8) | NA |
| B1/B2/B3 | NA | 38 (60.3)/21 (33.3)/4 (6.4) | NA |
| Previous intestinal resection | 15 (18.3) | 15 (23.8) | 0 |
| Perianal involvement/fistula | 12 (14.6) | 12 (19.0) | 0 |
| Extraintestinal manifestation | 18 (22.0) | 14 (22.2) | 4 (21.1) |
| IBD disease activity before COVID-19 diagnosis |
| HBI score for CD, median (IQR) | NA | 2 (0–2) | NA |
| Partial Mayo score for UC, median (IQR) | NA | NA | 1 (0–2) |
| Patients with endoscopy before COVID-19, n (%) | 39 (47.6) | 28 (44.4) | 11 (57.9) |
| SES-CD for CD (median, IQR) | NA | 1 (0–7) | NA |
| Mayo endoscopic score for UC (median, IQR) | NA | NA | 1 (0–2) |
| Patients with clinical active, n (%) | 18 (22.0) | 14 (22.2) | 4 (21.1) |
| Patients with endoscopic active, n (%) | 13 (15.9) | 9 (14.3) | 4 (22.1) |
| SES-CD in active CD, median (IQR) | NA | 9 (3–20) | NA |
| Mayo endoscopic score in active UC, median (IQR) | NA | NA | 2 (2–3) |
| Labs before diagnosis of COVID-19, median (IQR) |
| Hemoglobin, g/L | 132.5 (122.0–146) | 133.5 (122–146.5) | 131.5 (119–143) |
| Albumin, g/L | 40.3 (38.0–44.0) | 41.0 (37.2–43.5) | 42.0 (38.0–45.0) |
| C-reactive protein, mg/l | 4.0 (1.0–8.0) | 4.0 (2.0–8.0) | 2.0 (0.8–13.5) |
| Fecal calprotectin, mcg/g | 165 (36.5–320) | 165.5 (37.8–284.5) | 165 (33.5–716) |
|
